CHURCHILL MANAGEMENT Corp cut its holdings in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 1.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 366,695 shares of the biopharmaceutical company’s stock after selling 3,707 shares during the quarter. Pfizer comprises 0.4% of CHURCHILL MANAGEMENT Corp’s investment portfolio, making the stock its 24th largest holding. CHURCHILL MANAGEMENT Corp’s holdings in Pfizer were worth $18,789,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the business. Apella Capital LLC lifted its holdings in shares of Pfizer by 13.5% during the fourth quarter. Apella Capital LLC now owns 17,932 shares of the biopharmaceutical company’s stock worth $919,000 after buying an additional 2,130 shares during the last quarter. Coldstream Capital Management Inc. acquired a new position in shares of Pfizer during the fourth quarter worth approximately $8,560,000. Signature Wealth Management Group lifted its holdings in shares of Pfizer by 1.5% during the fourth quarter. Signature Wealth Management Group now owns 79,617 shares of the biopharmaceutical company’s stock worth $4,080,000 after buying an additional 1,162 shares during the last quarter. Woodstock Corp lifted its holdings in shares of Pfizer by 2.0% during the fourth quarter. Woodstock Corp now owns 134,130 shares of the biopharmaceutical company’s stock worth $6,873,000 after buying an additional 2,575 shares during the last quarter. Finally, Trinity Legacy Partners LLC raised its stake in shares of Pfizer by 3.7% in the fourth quarter. Trinity Legacy Partners LLC now owns 107,348 shares of the biopharmaceutical company’s stock valued at $5,501,000 after purchasing an additional 3,838 shares in the last quarter. 67.62% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on PFE shares. Wells Fargo & Company cut their target price on Pfizer from $50.00 to $44.00 and set an “equal weight” rating for the company in a research note on Friday. Jefferies Financial Group started coverage on Pfizer in a research note on Monday, March 6th. They issued a “hold” rating and a $43.00 target price for the company. UBS Group set a $45.00 target price on Pfizer in a research note on Tuesday. Credit Suisse Group cut their target price on Pfizer from $54.00 to $50.00 and set an “outperform” rating for the company in a research note on Wednesday, February 1st. Finally, Atlantic Securities dropped their price objective on Pfizer from $50.00 to $46.00 and set a “neutral” rating for the company in a research note on Wednesday, February 1st. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $50.38.
Pfizer Price Performance
Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.11. The business had revenue of $24.30 billion for the quarter, compared to analysts’ expectations of $24.40 billion. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.08 earnings per share. Equities research analysts expect that Pfizer Inc. will post 3.33 EPS for the current fiscal year.
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.